200731-31-3

Basic information

• Product Name: Methanaminium, N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N -methyl-, hexafluorophosphate(1-)
• CAS NO: 200731-31-3
• Molecular Formula: C10H15N6O.F6P
• Molecular Weight: 380.233
• Mol File: 200731-31-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Methanaminium, N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N -methyl-, hexafluorophosphate(1-)(CAS DataBase Reference)
• NIST Chemistry Reference: Methanaminium, N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N -methyl-, hexafluorophosphate(1-)(200731-31-3)
• EPA Substance Registry System: Methanaminium, N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N -methyl-, hexafluorophosphate(1-)(200731-31-3)

Safety Data

• Hazardous Substances Data: 200731-31-3(Hazardous Substances Data)

Downstream Products

• 258502-85-1 N-[5-(3-dimethylaminobenzamido)-2-methylphenyl]quinoline-6-carboxamide 
• 959369-96-1 5-(S)-Acetamidomethyl-3-[4'-(N,N-dimethylamino)carbonyl-3'-fluorophenyl]-oxazolidine-2-one 
• 224635-37-4 (R)-3-[2-(2-methoxyethoxy)acetylamino]-3-(4-aminophenyl)-propanoic acid methyl ester 
• 224635-17-0 (R)-3-[(2-amino-acetyl)amino]-3-(4-{3-methoxy-4-[3-(2-methylphenyl)ureido]phenyl-acetylamino}phenyl)propanoic acid 
• 261732-06-3 (S) 2-(2-Chloro-6-methyl-benzoylamino)-3-[1-(2,6-dichloro-benzoyl)-1,2,3,4-tetrahydro-quinolin-6-yl]-propionic Acid 
• 637020-44-1 2-(5-azidomethyl-4-chloro-3-trifluoromethyl-pyrazol-1-yl)-1-[4-(4-chlorophenyl)-piperazin-1-yl]-ethanone 
• 288580-54-1 ethyl (R) 3-{4-[2-(4-methoxy-2-o-tolylaminobenzoxazol-6-yl)acetylamino]phenyl}butanoate 
• 306767-90-8 (R) 3-[(5-methyl-isoxazole-3-carbonyl)-amino]-3-{4-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-propionic acid 
• 306767-88-4 [R] 3-(Acetyl-methyl-amino)-3-(4-{methyl-[(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-amino}:-phenyl)-propionic Acid 
• 301809-88-1 (3RS)-3-{5-[2-(2-o-tolylamino-3H-benzimidazol-5-yl)-acetylamino]-pyridin-2-yl}-butyric acid trifluoroacetate 

Relevant articles and documents

Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.